Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

CombinatoRx Halts Psoriasis Drug After Its Phase II Failure

Feb. 23, 2006

By Jennifer Boggs

Cleveland BioLabs Files $14M IPO For Radiation Protection

Feb. 23, 2006

By Jennifer Boggs

Precision’s Series B Adds $20M For Cancer Regimen

Feb. 22, 2006

By Jennifer Boggs

Precision’s Series B Adds $20M For Cancer Regimen

Feb. 22, 2006

By Jennifer Boggs

QLT's BPH drug doesn't show efficacy in Phase II study

Feb. 21, 2006

By Jennifer Boggs

QLT’s BPH Drug Fails To Show Efficacy In Phase II

Feb. 17, 2006

By Jennifer Boggs

QLT’s BPH Drug Fails To Show Efficacy In Phase II

Feb. 17, 2006

By Jennifer Boggs

Australia’s G2 Enters Novo Deal Valued At Up To $102M

Feb. 16, 2006

By Jennifer Boggs

Australia’s G2 Enters Novo Deal Valued At Up To $102M

Feb. 16, 2006

By Jennifer Boggs

YM’s Direct Offering Raises $40M For Drug Development

Feb. 15, 2006

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...